Self-Assembling Peptides for hiPSC-CM Maturation and Arrhythmia Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) result in underdeveloped phenotypes with fetal-like sarcomere organization, insufficient expression of adult myosin-heavy chains, and increased arrhythmogenic automaticity, posing a risk for potentially lethal ventricular arrhythmias.
Innovation Solution
Utilizing self-assembling peptides, such as RADA16, to accelerate the transition of hiPSC-CMs to adult-like gene expression profiles and enhance sarcomere organization, combined with flexible mesh nanoelectronics to monitor and improve vascularization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If self-assembling peptides are used to accelerate maturation, then adult-like gene expression and sarcomere organization are achieved, but arrhythmogenic automaticity is reduced
Solution Approach 1:
The patent applies parameter changes by using self-assembling peptides to alter the physical and chemical environment, which triggers a transition in cardiomyocyte phenotype from fetal to adult-like state. This includes changes in gene expression profiles, sarcomere organization, and electrophysiological properties, thereby resolving the contradiction between achieving mature phenotypes and reducing arrhythmogenicity.
Solution Approach 2:
Self-assembling peptides act as intermediaries that mediate the maturation process of cardiomyocytes. These peptides create a structured microenvironment that facilitates the transition from immature to mature phenotypes, enabling improved sarcomere organization while simultaneously reducing harmful arrhythmogenic automaticity.
2Reliability
If flexible mesh nanoelectronics are used to monitor transplanted cells, then arrhythmogenic automaticity is detected and reduced, but vascularization is enhanced
Solution Approach 1:
Flexible mesh nanoelectronics provide real-time feedback on the electrophysiological activity of transplanted cardiomyocytes. This monitoring capability enables detection of arrhythmogenic automaticity and facilitates及时调整 of treatment strategies, thereby improving the safety and reliability of cell transplantation while allowing vascularization to proceed.
Solution Approach 2:
The use of flexible mesh nanoelectronics as thin film structures allows for close contact with transplanted cells without impeding vascularization. These flexible structures can conform to the tissue architecture, enabling continuous monitoring while maintaining tissue perfusion and reducing mechanical stress on the developing vasculature.
3Manufacturing precision
If self-assembling peptides are used, then adult myosin-heavy chain expression is enhanced, but fetal-like sarcomere organization is replaced
Solution Approach 1:
The self-assembling peptides induce parameter changes in the cardiomyocyte population, shifting the expression profile from fetal to adult isoforms of myosin-heavy chains and other cardiac markers. This transformation is accompanied by reorganization of sarcomeric structures from disorganized fetal patterns to organized adult patterns, resolving the contradiction between achieving adult phenotype and eliminating fetal characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of self-assembling peptides and nanoelectronics reduces arrhythmogenic automaticity, promotes vascularization, and matures cardiomyocytes to an adult-like state, enhancing their safety and efficacy for cardiac cell therapy.
Implementation Method 1
Self-assembling peptides, such as RADA16, may accelerate the transition of hiPSC-CMs to adult-like gene expression profiles, enhanced sarcomere organization, and improved vascularization in the transplanted site
Data Source
AI summary
Disclosed herein are methods for induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) by combining the hiPSC-CMs with a self-assembling peptide (SAP). Also disclosed herein are compositions comprising induced pluripotent stem cell-derived cardiomyocytes and a self-assembling peptide.